Upexi Inc
UPXI4.910USD
+0.140+2.94%
Cierre 10/24, 16:00（ET）Cotizaciones retrasadas 15 min
187.91MCap. mercado
PérdidaP/E TTM
Más Datos de Upexi Inc Compañía
Upexi, Inc. is a brand owner specialized in the development, manufacturing and distribution of consumer products. The Company focuses on direct-to-consumer and Amazon brands. The Company’s brands include LuckyTail, PRAX, Cure Mushrooms, Moonwlkr, Gumi Labs, and Upexi Distribution. LuckyTail products consist of its flagship nail grinder and healthy all-natural pet supplements. Gumi Labs manufactures gummies and other products supporting its health and wellness products, including those products manufactured with hemp ingredients. Upexi Distribution manages the warehousing and logistic needs of the Company and provides storage, consolidation, assembly, Amazon preparation, distribution and fulfilment services to its brands and its manufacturing operation.
Información de Upexi Inc
Símbolo de cotizaciónUPXI
Nombre de la empresaUpexi Inc
Fecha de salida a bolsaJun 24, 2021
Director ejecutivo- -
Número de empleados64
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 24
Dirección3030 Rocky Point Drive
CiudadTAMPA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33607
Teléfono17013535425
Sitio Webhttps://upexi.com/
Símbolo de cotizaciónUPXI
Fecha de salida a bolsaJun 24, 2021
Director ejecutivo- -
Ejecutivos de Upexi Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Allan Marshall ,
Allan Marshall ,
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.51M
+899.43%
Dr. Gene Salkind, M.D.
Dr. Gene Salkind, M.D.
Independent Director
Independent Director
585.37K
+60.32%
Mr. Andrew J. Norstrud
Mr. Andrew J. Norstrud
Chief Financial Officer, Director
Chief Financial Officer, Director
349.14K
+252.17%
Mr. Thomas Charles Williams
Mr. Thomas Charles Williams
Independent Director
Independent Director
100.00K
--
Mr. Lawrence H. Dugan
Mr. Lawrence H. Dugan
Independent Director
Independent Director
--
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Allan Marshall ,
Allan Marshall ,
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.51M
+899.43%
Dr. Gene Salkind, M.D.
Dr. Gene Salkind, M.D.
Independent Director
Independent Director
585.37K
+60.32%
Mr. Andrew J. Norstrud
Mr. Andrew J. Norstrud
Chief Financial Officer, Director
Chief Financial Officer, Director
349.14K
+252.17%
Mr. Thomas Charles Williams
Mr. Thomas Charles Williams
Independent Director
Independent Director
100.00K
--
Mr. Lawrence H. Dugan
Mr. Lawrence H. Dugan
Independent Director
Independent Director
--
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q1
Por negocioUSD
Nombre
Ganancia
Proporción
Internally manufactured
9.26M
62.48%
Contract manufactured
2.79M
18.80%
Purchased as finished goods
2.78M
18.73%
Por regiónUSD
Nombre
Ganancia
Proporción
United States of America
14.57M
98.25%
Other
259.57K
1.75%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Internally manufactured
9.26M
62.48%
Contract manufactured
2.79M
18.80%
Purchased as finished goods
2.78M
18.73%
Estadísticas de accionistas
Actualizado: sáb., 18 de oct
Actualizado: sáb., 18 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
MMCAP Asset Management
21.98%
Samara Special Opportunities
7.69%
GSR Growth Investments LP
3.92%
Marshall (Allan)
2.57%
Pantera Capital Partners LP
2.26%
Otro
61.59%
Accionistas
Accionistas
Proporción
MMCAP Asset Management
21.98%
Samara Special Opportunities
7.69%
GSR Growth Investments LP
3.92%
Marshall (Allan)
2.57%
Pantera Capital Partners LP
2.26%
Otro
61.59%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
23.83%
Corporation
11.61%
Individual Investor
5.95%
Investment Advisor
5.51%
Investment Advisor/Hedge Fund
1.00%
Research Firm
0.26%
Bank and Trust
0.24%
Venture Capital
0.14%
Otro
51.45%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
53
23.37M
39.68%
+23.17M
2025Q2
46
10.18M
21.50%
+7.63M
2025Q1
42
311.78K
28.56%
-35.31K
2024Q4
42
307.62K
23.29%
-32.82K
2024Q3
40
303.51K
29.16%
-55.91K
2024Q2
40
319.39K
30.68%
-45.58K
2024Q1
42
328.34K
32.32%
-46.59K
2023Q4
42
319.26K
31.43%
-34.26K
2023Q3
40
369.15K
37.28%
-46.01K
2023Q2
44
368.80K
38.85%
-28.58K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
MMCAP Asset Management
12.94M
21.98%
+12.94M
--
Jul 16, 2025
Samara Special Opportunities
4.53M
7.69%
+4.53M
--
Aug 29, 2025
GSR Growth Investments LP
2.31M
3.92%
-1.00
-0.00%
Jun 30, 2025
Marshall (Allan)
1.51M
2.57%
+1.36M
+899.43%
Jul 16, 2025
Pantera Capital Partners LP
1.33M
2.26%
+1.33M
--
Jun 30, 2025
Rudick (Brian Benjamin)
838.60K
1.42%
+400.00K
+91.20%
Jul 16, 2025
Salkind (Gene)
585.37K
0.99%
+220.24K
+60.32%
Jul 16, 2025
NewGen Asset Management Limited
577.19K
0.98%
+577.19K
--
Jun 30, 2025
The Vanguard Group, Inc.
500.84K
0.85%
+500.84K
--
Jun 30, 2025
Kathmere Capital Management
2.19M
3.72%
+2.19M
--
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: lun., 6 de oct
Actualizado: lun., 6 de oct
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
Fecha
Tipo
Relación
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
Sep 27, 2024
Merger
20→1
